Welcome to our dedicated page for Quipt Home Medical news (Ticker: QIPT), a resource for investors and traders seeking the latest updates and insights on Quipt Home Medical stock.
Quipt Home Medical Corp. (QIPT) generates a steady flow of news as a U.S.-based home medical equipment provider focused on end-to-end respiratory care and in-home chronic disease management. Company press releases regularly discuss its role in providing in-home monitoring and disease management services for patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions in the United States healthcare market.
News coverage for QIPT commonly includes financial results and operational updates. For example, Quipt issues quarterly and annual earnings releases that highlight revenue trends, recurring revenue from equipment rentals and respiratory resupplies, Adjusted EBITDA, and operational metrics such as the number of unique patients served and set-ups or deliveries completed. These releases often include management commentary on business performance, revenue stabilization, and the contribution of acquisitions and partnerships.
Another major category of Quipt news involves strategic transactions. The company has announced acquisitions of durable medical equipment providers and a joint venture interest in Hart Medical Equipment, as well as a preferred provider agreement with Ballad Health. These items describe how Quipt works with health systems and hospitals to integrate home medical equipment and respiratory care into hospital discharge processes and post-acute care coordination.
More recently, Quipt’s news has featured corporate and M&A developments, including activist shareholder commentary and, most notably, the December 2025 announcement of a definitive Arrangement Agreement under which a special purpose acquisition vehicle funded by affiliates of Kingswood Capital Management and Forager Capital Management will acquire all outstanding Quipt shares for cash. This transaction, if completed, is expected to result in Quipt becoming a privately held company and its shares being delisted from The Nasdaq Capital Market and the Toronto Stock Exchange.
Investors and observers using this QIPT news page on Stock Titan can review these earnings announcements, acquisition and joint venture updates, health system partnership news, and transaction-related disclosures in one place, helping them understand how Quipt’s home medical equipment and respiratory care strategy is reflected in its public communications.
Quipt Home Medical (NASDAQ: QIPT) announced completion of its previously announced plan of arrangement on March 16, 2026, under which affiliates of Kingswood and Forager acquired all outstanding shares for US$3.65 per share.
Outstanding options and RSUs were cashed out and cancelled, and the shares will be delisted from NASDAQ and the TSX at close of business on March 17, 2026; the company intends to cease public reporting in Canada and the U.S.
Quipt Home Medical (NASDAQ: QIPT) received a final court order from the Supreme Court of British Columbia approving a plan of arrangement under which affiliates of Kingswood Capital and Forager Capital will acquire all shares for US$3.65 per share.
Assuming remaining conditions are satisfied, closing is expected by March 16, 2026, after which the company anticipates delisting from the TSX and NASDAQ and ceasing to be a reporting issuer. Arrangement agreement dated Dec 14, 2025; shareholder materials filed on SEDAR+ and EDGAR.
Quipt Home Medical (NASDAQ: QIPT) announced that shareholders approved a court‑supervised plan of arrangement to be acquired for US$3.65 per share. The special meeting on March 3, 2026 recorded 29,672,136 shares (≈66.93%) represented and strong support for the resolution.
The Company will seek a final order from the Supreme Court of British Columbia on March 5, 2026; completion remains subject to exchange and regulatory approvals.
Quipt Home Medical (NASDAQ: QIPT; TSX: QIPT) filed its definitive proxy circular and began mailing meeting materials for a special shareholder meeting on March 3, 2026 at 10:00 a.m. EST.
The Arrangement would sell all shares for US$3.65 per share (a 54% premium to the 30-day VWAP as of Dec 12, 2025). The board unanimously recommends the Arrangement. An interim order from the Supreme Court of British Columbia dated Jan 23, 2026 authorizes the meeting. Record date is Jan 22, 2026; proxy deadline is Feb 27, 2026. Directors/executives and Forager hold ~11.3% and ~9.5% respectively and have voting support agreements.
Quipt Home Medical (NASDAQ: QIPT) agreed to be acquired by a purchaser funded by affiliates of Kingswood Capital and Forager Capital for US$3.65 per share in cash. The deal values Quipt at approximately US$260 million including outstanding debt and is not subject to any financing condition. The per-share price represents a 162% premium to Quipt's unaffected May 19, 2025 price and a 54% premium to its 30-day VWAP as of December 12, 2025. Kingswood provided an equity commitment letter to fund the purchaser. Following closing, Quipt will become privately held and will cease reporting in the U.S. and Canada. The Quipt board unanimously recommends shareholder approval after receiving fairness opinions from Truist and Evans & Evans.
Quipt Home Medical (NASDAQ: QIPT) reported fourth-quarter and fiscal year 2025 results for the periods ended September 30, 2025. Q4 revenue was $68.3M, up 11% year‑over‑year, with sequential organic growth of 5% and recurring revenue at 80% of total. Q4 Adjusted EBITDA was $14.9M (21.8% margin); fiscal 2025 Adjusted EBITDA was $55.9M (22.8% margin). Reported net loss was $3.6M in Q4 and $10.7M for the year. Operating cash flow for FY2025 was $37.7M. Cash on hand was $12.9M with $12.7M total credit availability and Net Debt/Adjusted EBITDA leverage of 1.8x. Customer count rose 10% to 346,000 and total set‑ups increased 7% to 917,000.
Summary not available.
Summary not available.
Quipt Home Medical (NASDAQ: QIPT) has completed the acquisition of a 60% ownership stake in Hart Medical Equipment for $17.4 million, funded through senior credit facilities. The remaining 40% is held by multiple health systems and hospitals.
Hart generates $60 million in annual revenue and $7 million in Adjusted EBITDA, with expectations to reach $10+ million in annual Adjusted EBITDA within 6-9 months. The acquisition pushes Quipt's annualized run-rate revenue above $300 million, with anticipated Adjusted EBITDA exceeding $65 million post-integration.
Hart serves over 67,000 patients monthly and maintains strategic relationships with major health systems, being integrated into the discharge processes of more than 19 hospitals and affiliated care facilities across its network.
Quipt Home Medical (NASDAQ: QIPT) has rejected an unsolicited, non-binding proposal from Forager Capital Management (FCM) to acquire all outstanding shares at $3.10 per share. The Board highlights that this offer is 26% lower than FCM's January 2025 proposal of $3.90 per share, which was also rejected for undervaluing the company.
Since January, Quipt has made significant acquisitions, including a $6.6 million revenue medical equipment provider and a 60% stake in Hart Medical Equipment, adding $60 million in revenue and $7 million in Adjusted EBITDA. The Board criticizes FCM's tactics, including failure to disclose the January proposal in SEC filings and bypassing proper communication channels through Truist Securities.
The Board remains open to engaging with FCM under proper confidentiality agreements but emphasizes its commitment to maximizing long-term shareholder value.